156,746 Shares in Integra LifeSciences Holdings Co. (NASDAQ:IART) Purchased by Cannell & Spears LLC

Cannell & Spears LLC acquired a new stake in Integra LifeSciences Holdings Co. (NASDAQ:IART) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 156,746 shares of the life sciences company’s stock, valued at approximately $3,555,000. Cannell & Spears LLC owned approximately 0.20% of Integra LifeSciences at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the stock. Nisa Investment Advisors LLC increased its holdings in shares of Integra LifeSciences by 599.6% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company’s stock valued at $74,000 after purchasing an additional 2,800 shares in the last quarter. Empowered Funds LLC acquired a new stake in shares of Integra LifeSciences in the 4th quarter valued at $180,000. Romano Brothers AND Company bought a new stake in shares of Integra LifeSciences during the fourth quarter worth $204,000. Mitsubishi UFJ Asset Management UK Ltd. acquired a new position in shares of Integra LifeSciences during the fourth quarter valued at $204,000. Finally, Centiva Capital LP bought a new position in Integra LifeSciences in the third quarter valued at about $192,000. 84.78% of the stock is owned by institutional investors.

Integra LifeSciences Stock Up 1.4 %

Shares of NASDAQ IART opened at $21.99 on Tuesday. Integra LifeSciences Holdings Co. has a 52-week low of $16.81 and a 52-week high of $35.45. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. The stock has a market cap of $1.70 billion, a P/E ratio of -244.31, a P/E/G ratio of 0.73 and a beta of 1.23. The firm has a 50 day moving average price of $23.74 and a 200 day moving average price of $22.24.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings data on Tuesday, February 25th. The life sciences company reported $0.97 EPS for the quarter, beating analysts’ consensus estimates of $0.85 by $0.12. The business had revenue of $442.65 million during the quarter, compared to analysts’ expectations of $445.15 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The firm’s quarterly revenue was up 11.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.89 EPS. Analysts expect that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

Analysts Set New Price Targets

IART has been the topic of a number of research reports. Morgan Stanley started coverage on shares of Integra LifeSciences in a research report on Monday, December 2nd. They set an “underweight” rating and a $20.00 target price on the stock. Argus upgraded shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a report on Monday. Three investment analysts have rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, Integra LifeSciences has a consensus rating of “Hold” and a consensus price target of $23.00.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.